The earnings call highlighted significant progress in Daré's dual-path strategy and upcoming product launches, which are expected to drive revenue and expand their market presence. However, technical difficulties during the call and a working capital deficit were noted. Overall, the sentiment is optimistic with a focus on future growth.

Company Guidance

During the second quarter of 2025, Daré Bioscience provided guidance on its dual-path business strategy, which focuses on commercializing proprietary formulations through a 503B compounding channel while pursuing FDA approval. The company plans to launch its DARE to PLAY Sildenafil cream in Q4 2025, aiming to generate near-term revenue and address significant unmet needs in women's sexual health. In the same quarter, Daré reported $5 million in cash and cash equivalents, with a working capital deficit of $12.6 million. Post-quarter, they bolstered their balance sheet with $17.6 million from stock sales and a $6 million grant. R&D expenses decreased by 71% compared to Q2 2024, primarily due to nondilutive funding awards, contributing to a more efficient advancement of their clinical pipeline. Additionally, the company is pursuing consumer health expansion with nonprescription vaginal probiotics and continues to advance grant-funded programs like DARE-HPV and DARE-LARC1, showcasing a focused commitment to innovation in women's health.

Launch of DARE to PLAY Sildenafil Cream

Daré Bioscience is on track to support the commercial availability of DARE to PLAY Sildenafil cream through a 503B outsourcing facility in Q4 2025, marking a major milestone in women's sexual health.

Ovaprene Phase III Trial Progress

The independent Data and Safety Monitoring Board recommended the continuation of the Ovaprene Phase III study, with interim data showing no new safety or tolerability concerns. The potential for a $20 million payment from Bayer highlights significant commercial interest.

Financial Strengthening

After the quarter ended, Daré Bioscience received approximately $17.6 million in net proceeds from sales of common stock and a $6 million grant payment, significantly strengthening the balance sheet.

Dual Commercialization Pathway for DARE-HRT1

Daré is pursuing both FDA approval and a 503B compounding opportunity for DARE-HRT1, targeting availability in late 2026, aiming to tap into the $4.5 billion compounded hormone therapy market.

Expansion into Consumer Health

Daré is preparing to launch nonprescription vaginal probiotics, expanding its commercial platform and ensuring access to science-backed products for women's intimate health.

Daré Bioscience (DARE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DARE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.48 / -	-0.55	―	―	―
Aug 14, 2025	2025 (Q2)	-0.58 / -0.45	1.52	-129.61% (-1.97)	―
May 13, 2025	2025 (Q1)	- / -0.50	-0.84	40.48% (+0.34)	―
Mar 31, 2025	2024 (Q4)	-0.58 / -0.50	-0.84	40.48% (+0.34)	―
Nov 14, 2024	2024 (Q3)	-0.69 / -0.55	-1.094	49.73% (+0.54)	―
Aug 12, 2024	2024 (Q2)	-0.04 / 1.52	-1.2	226.67% (+2.72)	―
May 14, 2024	2024 (Q1)	-0.72 / -0.84	-1.08	22.22% (+0.24)	―
Mar 28, 2024	2023 (Q4)	-1.08 / -0.84	-2.28	63.16% (+1.44)	―
Nov 09, 2023	2023 (Q3)	-1.18 / -1.09	-0.96	-13.96% (-0.13)
Aug 10, 2023	2023 (Q2)	-1.18 / -1.20	0	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DARE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$2.07	$2.20	+6.28%
May 13, 2025	$2.89	$2.89	0.00%
Mar 31, 2025	$2.89	$2.90	+0.35%
Nov 14, 2024	$3.56	$3.21	-9.83%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Daré Bioscience Inc (DARE) report earnings?

Daré Bioscience Inc (DARE) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Daré Bioscience Inc (DARE) earnings time?

Daré Bioscience Inc (DARE) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DARE EPS forecast?

DARE EPS forecast for the fiscal quarter 2025 (Q3) is -0.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing